KAHR Medical
PrivateLast Round
VC Round
Jan 8, 2026
Est. Valuation
$16M
Total Funding Raised
$47M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
KAHR Medical operates in Healthcare & Life Sciences and is based in Jerusalem. Its latest recorded funding round was a VC Round in January 2026.
KAHR Medical is a biotechnology company that develops dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems to treat cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
KAHR Medical Comparables
Compare KAHR Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QLSF Biotherapeutics | 76% | |
| ALX Oncology | 76% | |
| Trojan Bio | 75% |
For institutional investors. Book with your work email.
KAHR Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 8, 2026 | ||||
| Series B | Oct 14, 2025 | ||||
| Series D Extension | Nov 17, 2022 | ||||
| VC Round | Jun 16, 2021 | ||||
| VC Round | Feb 25, 2020 | ||||
Series B | Dec 15, 2015 |
For institutional investors. Book with your work email.
KAHR Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DSC Investment | Series B |
| Korea Investment Partners | Series B |
| Mirae Asset | VC Round, Series D Extension |
| Israel Innovation Authority | Seed |
| Flerie Invest | VC Round |
| The University of Texas MD Anderson Cancer Center | VC Round |
| Consensus Business Group | Series D Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
Raised $22M led by amoon-fund, Cancer Focus Fund, Peregrine Ventures, Flerie, and Flerie AB.
- Oct 14, 2025
$22M round completed.
For institutional investors. Book with your work email.
KAHR Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about KAHR Medical's valuation, stock price, and market status.
Is KAHR Medical a public or private company?
KAHR Medical is a private company.
What is the current stock price of KAHR Medical?
KAHR Medical is a private company, so its shares have no public market price. Caplight tracks KAHR Medical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is KAHR Medical worth (valuation)?
KAHR Medical's valuation is estimated at $16.0M based on funding round data.
Can I buy KAHR Medical stock?
KAHR Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was KAHR Medical's last funding round?
KAHR Medical's most recent funding round was VC Round on January 8, 2026.
Who are the main investors in KAHR Medical?
Key investors in KAHR Medical include DSC Investment, Flerie Invest, aMoon, Cancer Focus Fund, Pavilion Capital.
Will KAHR Medical IPO soon?
No public IPO plans have been announced for KAHR Medical.
How can I track KAHR Medical secondary market activity?
Caplight tracks bids, offers, and trades in KAHR Medical's shares on secondary markets.